BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Get Free Report)‘s stock had its “outperform” rating reissued by Wedbush in a research note issued on Wednesday, Benzinga reports. They currently have a $25.00 target price on the stock. Wedbush’s target price would indicate a potential upside of 182.17% from the stock’s previous close.
Several other brokerages also recently issued reports on BBOT. Oppenheimer started coverage on BridgeBio Oncology Therapeutics in a research note on Monday, June 22nd. They set an “outperform” rating and a $22.00 target price on the stock. Wall Street Zen upgraded BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a report on Thursday, June 18th. UBS Group cut shares of BridgeBio Oncology Therapeutics to an “overweight” rating in a research note on Wednesday, July 8th. Finally, JPMorgan Chase & Co. reduced their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, BridgeBio Oncology Therapeutics has an average rating of “Moderate Buy” and an average target price of $24.50.
Read Our Latest Stock Analysis on BBOT
BridgeBio Oncology Therapeutics Stock Performance
BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($705.20) EPS for the quarter. On average, sell-side analysts forecast that BridgeBio Oncology Therapeutics will post -2.79 EPS for the current fiscal year.
Hedge Funds Weigh In On BridgeBio Oncology Therapeutics
Several institutional investors have recently bought and sold shares of BBOT. Paradigm Biocapital Advisors LP grew its stake in shares of BridgeBio Oncology Therapeutics by 21.2% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock worth $28,317,000 after buying an additional 395,608 shares in the last quarter. Laurion Capital Management LP raised its position in shares of BridgeBio Oncology Therapeutics by 40.1% during the 4th quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock valued at $18,341,000 after buying an additional 419,138 shares in the last quarter. Armistice Capital LLC raised its position in shares of BridgeBio Oncology Therapeutics by 142.7% during the 4th quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock valued at $12,520,000 after buying an additional 588,000 shares in the last quarter. Geode Capital Management LLC raised its position in shares of BridgeBio Oncology Therapeutics by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock valued at $7,039,000 after buying an additional 20,385 shares in the last quarter. Finally, Catalio Capital Management LP bought a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $5,142,000. Institutional investors own 54.89% of the company’s stock.
About BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.
BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.
Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.
Featured Articles
- Five stocks we like better than BridgeBio Oncology Therapeutics
- Lululemon’s Problems May Not Be a Warning for Every Athleticwear Stock
- Roper Technologies In Rebound and a Hot Buy Despite Insider Selling
- PayPal’s Takeover Story Ended, But Its Turnaround Story Didn’t
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
Receive News & Ratings for BridgeBio Oncology Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Oncology Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
